Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALPL | P05186 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989354 | 0.89 | ALOX12 (0.56) | DDAH1MAPK1ALPLKDM4EMAPT | |
| SCHEMBL30207649 | 0.86 | DDAH1 (0.61) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL2680248 | 0.86 | CYP3A4 (0.64) | DDAH1MAPK1ALPLPOLBPKM | |
| SCHEMBL13050694 | 0.86 | CYP3A4 (0.64) | DDAH1MAPK1ALPLPOLBPKM | |
| SCHEMBL133478 | 0.86 | DDAH1 (0.61) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL20646170 | 0.86 | DDAH1 (0.61) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL8025715 | 0.86 | DDAH1 (0.61) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL20677814 | 0.85 | DDAH1 (0.63) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL4106172 | 0.84 | DDAH1 (0.64) | DDAH1MAPK1ALPLKDM4EPOLB | |
| SCHEMBL6346692 | 0.83 | DDAH1 (0.57) | DDAH1MAPK1ALPLKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| CN-116810216-A | Water-soluble pre-flux and surface treatment method | 株式会社田村制作所 | 2023-09-29 | — | — | CN | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220395487-A1 | RIG-I INNATE IMMUNE RECEPTOR ANTAGONISTS AND METHODS OF USING SAME | UNIV YALE (US) | 2022-12-15 | — | — | US | disclosed |
| EP-0791671-B1 | Surface treating agent for copper or copper alloy | SHIKOKU CHEM (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5795409-A | MIXTURE OF A (BENZ)IMIDAZOLE COMPOUND, CHELATE COMPOUND AND IRON | SHIKOKU CHEMICALS CORPORATION (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0791671-A1 | Surface treating agent for copper or copper alloy | SHIKOKU CHEMICALS CORPORATION (JP) | 1997-08-27 | — | — | EP | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5348590-A | Surface treating agent for copper or copper alloys | HITACHI, LTD. (JP) | 1994-09-20 | — | — | US | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | DDAH1 2242/4885MAPK1 272/4885ALPL 3046/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | DDAH1 2237/4885MAPK1 2988/4885ALPL 2209/4885 |
| US-20220395487-A1 | RIG-I INNATE IMMUNE RECEPTOR ANTAGONISTS AND METHODS OF USING SAME | MAVS, HAVCR2, IRF3 | DDAH1 2400/4885MAPK1 3608/4885ALPL 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.